Results 51 to 60 of about 3,619 (165)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 12, Page 1673-1684, June 2026.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo, Sepideh Mehravar, Ellen Choi, Ju Dong Yang, Hyun‐Seok Kim, Yun Wang, Aarshi Vipani, Hirsh D. Trivedi, Walid Ayoub, Parnian Naji, Alexander Kuo, Chun‐Ying Wu, Lorenzo Leggio, Juan Pablo Arab   +13 more
wiley   +1 more source

Drug therapy for alcohol dependence in primary care in the UK: A Clinical Practice Research Datalink study.

PLoS ONE, 2017
AimTo evaluate drug therapy for alcohol dependence in the 12 months after first diagnosis in UK primary care.DesignOpen cohort study.SettingGeneral practices contributing data to the UK Clinical Practice Research Database.Participants39,980 people with ...
Andrew Thompson, Darren M Ashcroft, Lynn Owens, Tjeerd P van Staa, Munir Pirmohamed   +4 more
doaj   +1 more source

A Membrane‐Centric Plasma Lipidomic Signature of Response to Long‐Acting Naltrexone in Alcohol Use Disorder

Addiction Biology, Volume 31, Issue 5, May 2026.
In this responder‐enriched lipidomic substudy, response to long‐acting naltrexone in alcohol use disorder was associated with coordinated remodelling of plasma membrane phospholipids. The signature involved PEMT‐related PC/PE shifts, Lands‐cycle acyl chain editing, and cross‐headgroup redistribution of n‐3 PUFAs and arachidonic acid, defining a ...
Liyao Huang, Bojie Zhou, Qinling Ou, Jubo Yin, Xiwen Tian, Xuhui Zhou   +5 more
wiley   +1 more source

Virtual Reality–Based Cue Exposure and Aversion Therapy for Alcohol Dependence: A Randomized Controlled Trial

Addiction Biology, Volume 31, Issue 5, May 2026.
Virtual reality–based cue exposure therapy and aversion therapy were evaluated in male inpatients with alcohol dependence. The combined VR‐CET+AT intervention reduced craving and alcohol‐related attentional bias beyond standard care, whereas relapse rates did not differ significantly at 4 or 12 weeks.
Haoyu Zhao, Xiaotong Ying, Xiaoyu Du, Genhui Ren, Hongdu Deng, Wenhui Li, Jiali Wang, Ming Chen, Zihang Shao, Jingshu Zhang, Lanci Liu, Jie Zhang, Ping Cui, Chunyan Li, Xinyou Wang, Ying Xu, Junjun Zhang, Dan Wang, Chuansheng Wang   +18 more
wiley   +1 more source

Towards Mechanism‐Informed Treatments for Mental Health

Journal of Neurochemistry, Volume 170, Issue 5, May 2026.
Neuropsychiatric disorders impose a major global health burden, and current treatments, which historically mostly targeted dopamine and serotonin dysfunctions, often provide only partial, symptomatic relief. This review highlights emerging evidence that additional neuromodulator systems, including acetylcholine, norepinephrine, and endocannabinoids ...
Iker Bengoetxea de Tena, Farhanah Nabilah Sallie, Arvie Rodriguez Abiero, Beatrice Rizzi, Leandro Gabriel Champarini, Elisa Corti, Gianluca Masella, Ariel L. Dunn, Luisa Bandeira Binder, Tyler J. Wenzel, Agustin I. Robles, Roberta G. Anversa, Cécilia Tremblay, Aliance Romain Fokoua, Randriely Merscher Sobreira de Lima, Mateus D'Ávila, Trang T. T. Truong, Jessica C. Pierce, Rui S. Rodrigues, Luis Dinamarca‐Villarroel, Felipe Borges Almeida, Aino‐Kaisa Piironen, Andrey F. L. Aguiar, Andrés M. Jaramillo, Lucas Santos, Anja de Lange, David J. Nutt, Andrew J. Lawrence   +27 more
wiley   +1 more source

The Clinical Manifestation of Homozygous Huntington's Disease

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Huntington's disease is an incurable neurodegenerative disease with deficits in many areas including cognitive, psychiatric, and most notably, motor. It is autosomal dominant, meaning one affected allele is enough to express the condition.
Brishti Sengupta, Pritha Dasgupta
wiley   +1 more source

Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects

Scientific Reports, 2017
Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict ...
David J. Hinton, Marely Santiago Vázquez, Jennifer R. Geske, Mario J. Hitschfeld, Ada M. C. Ho, Victor M. Karpyak, Joanna M. Biernacka, Doo-Sup Choi   +7 more
doaj   +1 more source

Assessment of early return to drinking in surviving patients with alcohol‐associated hepatitis

Alcohol, Clinical and Experimental Research, Volume 50, Issue 4, April 2026.
Among survivors of alcohol‐associated hepatitis, nearly one‐third resumed drinking within 6 months. High baseline drinking frequency and lower educational attainment independently predicted relapse, highlighting a critical window for early, structured addiction‐focused interventions.
Thomas G. Cotter, Mack C. Mitchell, Wanzhu Tu, Qing Tang, Yunpeng Yu, Samer Gawrieh, Craig J. McClain, Ramon Bataller, Naga Chalasani, Vijay H. Shah, Arun J. Sanyal, Gyongyi Szabo, Srinivasan Dasarathy   +12 more
wiley   +1 more source

Anticraving therapy for alcohol use disorder: A clinical review

Neuropsychopharmacology Reports, 2018
Aim In this review, the author focused on anticraving therapy for alcohol use disorder (AUD) defined by DMS‐5. A comprehensive review was carried out on the available published papers on anticraving drugs for treating AUD patients.
Winston W. Shen
doaj   +1 more source

Participant Demographic and Baseline Drinking Factors Can Predict Alcohol Use Disorder Pharmacotherapy Clinical Trial Completion and Drinking Outcomes

Alcohol, Clinical and Experimental Research, Volume 50, Issue 4, April 2026.
Five multisite AUD pharmacotherapy trial data were merged to explore participant prestudy characteristics as outcome predictors. Pre‐randomization “days since last drink” significantly predicted three drinking outcomes. Further analyses suggested that more than 3–5 days of consecutive abstinence would reduce chances of finding a significant medication ...
Michaela Hoffman, Raymond F. Anton, Arnie Aldridge   +2 more
wiley   +1 more source